TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07226206: A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Sponsor: Hoffmann-La Roche · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$525,300

Rescue Site Savings

+$350,200

Unlock Full NCT07226206 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07226206 Rescue Dossier →